Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report

Huang, Jie; Zhang, Shi-Ling; Zhou, Chaozheng; Huang, Weiye; Luo, Peng; Chen, Hua-Jun; Yang, Jin-Ji

doi:10.1016/j.jtocrr.2022.100338

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 45 , 49 Recently, the first case of a transformed SCLC from ALK -rearranged NSCLC using an analysis of the genomic and transcriptomic landscape of paired pre- and post-HT tissues was reported. 54 The findings indicated that no alterations or loss of functions were detected in TP53 or Rb1 , suggesting that the mechanism of HT to SCLC in ALK -rearranged NSCLC may differ from that in EGFR -mutated NSCLC. However, the number of paired-sample analyses was small, requiring further studies to examine the mechanistic differences of HTs between ALK -rearrangements and EGFR mutations.…”

Section: Ht Induced By Agents Other Than Egfr-tkismentioning

confidence: 88%

Histologic transformation in lung cancer: when one door shuts, another opens

2022

View full text Add to dashboard Cite

Histologic transformation (HT) is a major cause of drug resistance to therapy in patients with lung cancer. HTs to small-cell lung cancer (SCLC) have been reported frequently in patients with epidermal growth factor receptor ( EGFR)-mutated lung cancer. Although HTs have an impact on the clinical outcomes in patients owing to a high refractoriness to treatments, there is limited data on the prevalence, causes, mechanisms, treatment efficacy, and future treatment strategies. In this review, we assess the literature regarding HTs comprehensively, including those describing EGFR-tyrosine kinase inhibitors, other molecular targeted drugs, and immune checkpoint inhibitors. Furthermore, we discuss the mechanisms of HTs and the lineage plasticity to SCLC and squamous cell carcinoma in lung cancer. In addition, we summarize the treatment efficacy and future perspectives of HTs in patients with lung cancer, and propose better management strategies for this group of patients.

show abstract

Section: Ht Induced By Agents Other Than Egfr-tkismentioning

confidence: 88%